Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 11, 2026, discloses the vesting of conditional share awards and subsequent sales of shares to meet tax liabilities for Persons Discharging Managerial Responsibilities (PDMRs) and their Persons Closely Associated (PCAs). The transactions relate to awards granted in 2023 under the GSK Share Value Plan, which vested on February 9, 2026.
Key Financial Metrics
The filing does not contain corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific equity transactions involving the following instruments and prices:
- Ordinary Shares (GB00BN7SWP63): Vested at £0.00; Sold at £21.9082 per share on the London Stock Exchange.
- American Depositary Shares (US37733W2044): Vested at $0.00; Sold at $59.0729 per share on the New York Stock Exchange.
Material Changes and Transaction Details
The filing reports the following transactions executed on February 9, 2026:
| Executive / PCA | Position | Instrument | Vested Volume | Sold Volume (Tax) | Sale Price |
|---|---|---|---|---|---|
| Lynn Baxter | President, Europe | Ordinary Shares | 10,050 | 4,084 | £21.9082 |
| Mike Crichton | President, International | Ordinary Shares | 10,050 | 3,920 | £21.9082 |
| Maya Martinez-Davis | President, US | ADS | 10,658 | 2,789 | $59.0729 |
| Nina Mojas | President, Global Product Strategy | Ordinary Shares | 23,120 | 6,104 | £21.9082 |
| Victoria Whyte | SVP & Company Secretary | Ordinary Shares | 10,050 | 4,724 | £21.9082 |
| Neil Falkingham | PCA of Lynn Baxter | Ordinary Shares | 10,050 | 4,373 | £21.9082 |
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is a statutory notification of insider trading activity required under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the current market price of GSK Ordinary Shares and ADS against the transaction prices (£21.9082 and $59.0729) to assess execution timing.
- Confirm the total number of shares sold to meet tax liabilities versus the total vested to understand the net retention by executives.
- Review the GSK Share Value Plan terms to understand the vesting conditions attached to the 2023 awards.
- Check subsequent filings for any additional sales by these executives that may not be covered in this specific notification.